Home > Boards > US Listed > Medical - Healthcare > TransEnterix Inc. (TRXC)

The stock has recovered a bit recently, and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
TransEnterix Schedules Third Quarter Financial and Operating Results Conference Call for November 5, 2020 Business Wire - 10/26/2020 6:55:00 AM
TransEnterix Announces First Pediatric Surgical Cases with Senhance® Surgical System Business Wire - 10/13/2020 6:55:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/9/2020 5:26:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2020 5:05:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/8/2020 4:31:26 PM
TransEnterix Announces Toshima Hospital in Japan to Initiate a Senhance® Digital Laparoscopy Program Business Wire - 10/7/2020 6:55:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 5:40:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 5:38:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 5:37:16 PM
TransEnterix Ushers in New Era of Robotic Surgery with First Usage of Machine Vision Capabilities Business Wire - 9/23/2020 6:55:00 AM
トランスエンテリックスがSenhance手術システムの日本における研修センター設立を発表 Business Wire - 9/16/2020 7:01:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2020 2:46:31 PM
TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System Business Wire - 9/14/2020 6:55:00 AM
TransEnterix to Present at the H. C. Wainwright 22nd Annual Global Investment Conference Business Wire - 9/8/2020 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/25/2020 7:07:03 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/25/2020 7:04:57 PM
TransEnterix Announces New Employment Inducement Grant Business Wire - 8/25/2020 6:15:00 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/14/2020 4:34:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2020 4:32:06 PM
TransEnterix Announces Appointment of Shameze Rampertab as Chief Financial Officer Business Wire - 8/13/2020 6:55:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 6:06:38 AM
TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2020 Business Wire - 8/5/2020 4:05:00 PM
TransEnterix Announces Submission of General Surgery Expansion in the US Business Wire - 8/4/2020 6:55:00 AM
TransEnterix Announces Maastricht University Medical Center+ in the Netherlands to Initiate Program with the Senhance Surgica... Business Wire - 7/27/2020 6:50:00 AM
TransEnterix Schedules Second Quarter Financial and Operating Results Conference Call for August 5, 2020 Business Wire - 7/22/2020 6:55:00 AM
investora2z   Thursday, 10/31/13 07:19:31 AM
Re: None
Post # of 7716 
The stock has recovered a bit recently, and the volumes have been slightly better. It is up 464% on a ytd basis, and 393% up on 52 week basis. The main reason for the recent buoyancy is the merger with TransEnterix. The merger is expected to change the fortunes of the combined entity, especially in light of the $30 million raised by SafeStitch prior to the merger. The TransEnterix investors contributed two-thirds of this amount ($19.7 million), and Dr. Frost (along with other investors), invested the balance ($10.5 million). The combined entity is financially stronger than how the two companies were individually. Resources are extremely important for companies at the development stage, and backing of Dr. Frost gives confidence to the management. He is on the board of the combined company, and that may help it explore partnerships with others. Frost is known for exploring synergies between his companies. For example, the collaboration between OPKO Health (OPK) and Biozone Pharmaceuticals (BZNE) is likely to help both companies. Biozone owns the high potential proprietary drug delivery technology QuSomes, and OPKO has taken the license to test and use it for commercialization. The merger is expected to help TransEnterix develop its ability to bring flexible minimally invasive surgical technologies to the commercialization stage. The funds will help SafeStitch develop its robotic system SurgiBot and other products. Further, the two companies are expected to have synergies. The expected benefits of the merger will take time to translate into tangible results. The large up move in a short span of time makes the stock vulnerable to corrections due to profit booking. However, the support of Frost can take the stock much further than where it is right now. It may be good to tag along, but with a clear exit strategy in mind. The risks-reward is getting a bit unfavorable.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences